purtolimab

Purtolimab (HX008) is a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor. Developed by Lepu Biopharma, it acts as an immune checkpoint inhibitor by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade prevents the inhibitory signaling that typically suppresses T-cell activity in the tumor microenvironment, thereby restoring the immune system's ability to identify and destroy cancer cells. Purtolimab is approved in China for the treatment of patients with unresectable or metastatic melanoma who have failed previous systemic therapy, as well as for patients with advanced solid tumors that are microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) who have progressed following prior treatment.

Brand names

Puyouheng普佑恒

Other names

purtolimab